FDA Accepts Supplement for Levetiracetam ANDA204754 by Aiping Pharm
The FDA has accepted a supplemental application for ANDA204754, a generic version of levetiracetam, from Aiping Pharm.
Asset / Drug
Drug and asset intelligence for Levetiracetam with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.